As a diabetes educator, I know how passionate the CDCES community is about providing the best care for patients with diabetes and improving best practices for glycemic management. Certified Diabetes Care and Education Specialists (CDCES), formerly known as Certified Diabetes Educators (CDE), are also the most overburdened, and championing glycemic management initiatives is often an uphill battle.
At Glytec, we share your passion for changing the insulin management status quo. As the pioneer in data-driven glycemic management software, our mission is to improve the lives of patients managing glycemic issues, and those who administer their care, by optimizing insulin therapy.
This guide to eGlycemic Management Software (eGMS) for CDCESs will outline what eGMS is, how it can streamline clinician workflows, and how implementing it will benefit both your hospital and your #1 priority: patients.
eGMS is diabetes management software that uses data-driven algorithms to provide personalized insulin dosing recommendations at the point of care. eGMS effectively replaces sliding scale insulin therapy and paper protocols in a hospital.
Using eGMS, clinicians are able to get patients into target blood glucose range quickly and safely, reducing incidence of hypo- or hyperglycemia.
Glytec’s insulin dosing software is FDA-cleared and approved for use in IV insulin therapy, subcutaneous (SubQ) insulin therapy, and hospital-to-home discharge recommendations for both adult and pediatric patients.
eGMS can help your health system in a multitude of ways. This software can:
Yes, eGMS reduces rates of hypoglycemia and hyperglycemia. In fact, Glytec’s eGMS is proven to reduce incidence of severe hypoglycemia almost entirely (by 99.8%). This is attributed to the use of personalized dosing recommendations rather than one-size-fits-all therapies, as well as to workflow enhancements such as reminders for timely BG checks.
Sometimes, healthcare providers using standard therapies opt to “keep patients sweet,” erring on the side of hyperglycemia. But because eGMS is so effective at precisely controlling blood glucose, it enables clinicians to get patients into target range without overshooting into hyperglycemia.
The net effect is that patients can be brought into a safe BG range faster and be moved more quickly into a step-down unit or sent home.
Yes, eGMS can help hospitals promote the adoption of basal-bolus insulin (BBI) therapy among clinicians.
In one case study, we found that use of BBI went up from 5% to 96% after the implementation of eGMS. This is because the software does the calculations for the clinician, reducing the need for complex calculators or time-consuming paper protocols.
Additionally, eGMS systems like Glytec’s provide analytics that can be used to demonstrate the positive impact of BBI therapy on patient safety and quality of care, helping maintain buy-in from hospital leadership and increasing accountability for clinicians.
Yes, eGMS leads to better patient outcomes. Compared to usual care, Glytec’s insulin dosing software has been proven to reduce hypoglycemia rates, 30-day readmissions, average length of stay, and time-to-target blood glucose.
Yes, eGMS can reduce insulin dosing errors. Unlike paper protocols, Glytec’s eGMS can integrate directly with EHR to import patient demographic and lab data, which eliminates the risk of transcription errors.
Glytec also offers GlucoView®, an eGMS module that simplifies nursing workflows for timely monitoring of blood glucose. GlucoView provides a centralized dashboard of primary glycemic status indicators for all patients in a unit, including last BG test results, current infusion rates, and countdown timers specifying when BG checks are next due.
GlucoView helps foster communication and coordination within clinical care teams, especially during shift changes.
As a CDCES, we know you’re not solely responsible for making decisions about procuring diabetes management software. That’s why Glytec works hard to assist glycemic management champions in getting buy-in from hospital leadership.
One helpful conversation starter: eGMS doesn’t just improve patient safety and quality of care, it also offers significant financial savings for the hospital. Indeed, one medical center we studied saved nearly $10 million in the first year using our eGMS (about $2,934 per hypoglycemic event).
Glytec created eGMS because we believe in optimized insulin management. If you share our mission, we encourage you to reach out and see how we can work together for your hospital.
ECO #0891-A
©Copyright 2023 Glytec, LLC on behalf of Aseko, Inc. | Terms of Use | Legal Disclaimer | Privacy Policy | Contraindications, Warnings and Precautions
The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional’s clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.
Glucommander™ is only available for use in the United States.
This site is only intended for use in the United States.
Aseko is a registered trademark of Aseko, Inc.